Almirall S.A. Stock
Your prediction
Pros and Cons of Almirall S.A. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Almirall S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Almirall S.A. | 0.360% | 2.698% | 4.231% | -6.737% | -1.122% | -35.178% | - |
| Sihuan Pharmaceutical Holdings Group Ltd. | -1.750% | 1.786% | -6.557% | -35.955% | -16.788% | -82.831% | -75.000% |
| Recordati SpA | -1.500% | 8.124% | 2.099% | 27.048% | 9.318% | 14.807% | - |
| Swedish Orphan Biovitrum Ab | -2.240% | 4.305% | -2.269% | -0.768% | -3.645% | 64.034% | 20.549% |
News
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
This press release features multimedia. View the full release